Skip to content

TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT

The Use of Transversus Abdominis Plane (TAP) Block in Autologous Breast Reconstruction Donor Site: A Randomized, Double-blind, Placebo-controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01398982
Enrollment
93
Registered
2011-07-21
Start date
2011-07-31
Completion date
2014-02-28
Last updated
2015-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal/ Donor Site, DIEP or Free MS-TRAM Breast Reconstruction, Local Pain Management, Transversus Abdominis Plane (TAP) Block Catheter

Brief summary

Breast reconstruction using a patient's own abdominal tissue is one of the most common methods for restoring mastectomy defects for breast cancer patients. Despite its increasing popularity and safety, the abdomen remains a major source of postoperative pain. Adequate pain control is important as it has been shown to reduce medical complications, in-hospital death, shortens hospital stay, lessen chronic pain and disability, and in turn lower health-care costs. The current postoperative pain relief protocol consists primarily of a patient-controlled anesthesia device delivering intravenous opioids. Opioids can cause numerous side-effects such as sedation, headache, nausea, vomiting, breathing difficulties, bladder and bowel dysfunction. A promising approach to provide postoperative pain control of the abdominal incision is the newly developed transversus abdominis plane (TAP) peripheral nerve block. Although the TAP block has been found to be an effective pain-relief following major abdominal surgeries, its use has never been studied for breast reconstruction using abdominal tissue. Therefore, the investigators propose to rigorously study the efficacy of a TAP block in reducing postoperative abdominal pain following abdominal tissue breast reconstruction. This study has significant implications in improving both clinical care and health outcomes in patients undergoing this common method of breast reconstruction technique.

Detailed description

1\. Statement of Objectives/Specific Aims The transversus abdominis plane (TAP) block is a newly developed block involving T6-L1 nerves that supply the anterior abdominal wall. Its effectiveness has been reported following major abdominal surgeries, but not following abdominally-based autologous tissue breast reconstruction. Thus, we propose a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of TAP block in improving pain symptomatology following abdominally-based, autologous tissue breast reconstruction. The primary objective of this study is to compare the mean total opioid consumption in the first postoperative 48 hours between the control and study groups in intravenous morphine equivalent units. By directly blocking the neural afferents, the mean opioid consumption will be significantly lower in the group receiving intermittent local anaesthetic boluses compared to the placebo group through a TAP catheter. The secondary outcomes of interest are to compare the following parameters: A. Continuous outcomes i. Total in-hospital cumulative opioid consumption ii. Total in-hospital cumulative anti-nausea consumption iii. Quality of Recovery (QOR) score (0-18) iv. Duration of hospital stay B. Repeated measures outcomes In Hospital postoperative measures: i. Daily pain intensity scores at rest and with movement using a visual pain analogue scale (0-10) ii. Postoperative nausea and vomiting (score of 0-3) iii. Sedation score Long-term chronic pain, anxiety, function, and quality of life (QOL) measures: iv. Pain disability index v. Short-form McGill Pain Questionnaire vi. Hospital Anxiety and Depression Scale vii. Short-form 36 C. Time to event outcomes i. Time to first bowel movement ii. Time to ambulation Hypothesis: Compared to the control group, the TAP block group will have a statistically significant reduction in total in-hospital consumption of opioids, pain scores and side-effects from opioid use such as sedation, nausea, and vomiting. This should also result in a greater QOR score in the TAP block group. Surgical milestones such as time to ambulation, first bowel movement, and duration of hospital stay will also be reduced in the TAP block group. In addition, we hypothesize less acute postoperative pain achieved using the TAP block will result in a reduction in chronic pain and disability, anxiety and depression, and improved QOL in the long-term.

Interventions

DRUGBupivacaine (study group)

At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.

DRUGIsotonic saline (control group)

At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.

Sponsors

Canadian Society of Plastic Surgeons
CollaboratorOTHER
The Plastic Surgery Foundation
CollaboratorOTHER
University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

-Pre-operative eligibility: * Patients above the age of 18, no upper age limit * English-speaking * Delayed reconstruction (mastectomy already performed) or immediate reconstruction (mastectomy at the same time as reconstruction) * Reconstruction using abdominal tissues including free MS-TRAM or DIEP

Exclusion criteria

* Patient refusal * Inability to give informed consent * BMI \> 40 * Allergy to Bupivacaine * Known cardiac or liver disease (contraindicated for Bupivacaine use) * Patients who will undergo any of the following: * Implant breast reconstruction * Combined implant and autologous tissue reconstruction * Non-abdominally based autologous tissue reconstruction * Nonmicrosurgical abdominally based breast reconstruction (pedicled TRAM flap) * Drug addiction * Opioid tolerance defined as preoperative opioid use of \>50 mg PO morphine equivalent * Psychiatric illness

Design outcomes

Primary

MeasureTime frameDescription
Mean Total Opioid Consumptionfirst postoperative 48 hoursThe primary objective of this study is to compare the mean total opioid consumption in the first postoperative 48 hours between the control and study groups in intravenous morphine equivalent units. By directly blocking the neural afferents, the mean opioid consumption will be significantly lower in the group receiving intermittent local anaesthetic boluses compared to the placebo group through a TAP catheter.

Secondary

MeasureTime frameDescription
Daily Pain Intensity Scores at Rest and With MovementIn Hospital postoperative measures, average 4-5 daysDaily pain intensity scores at rest and with movement using a visual pain analogue scale (0-10)
Pain DisabilityHospital discharge, average 4-5 days, 6 months and 1 year following dischargePain Disability Index Scores
First Bowel MovementIn-patient hospital stay, average 4-5 daysTime to first bowel movement (# of days)
Anti-nausea ConsumptionIn-patient hospital stay, average 4-5 daysTotal in-hospital cumulative anti-nausea consumption
Quality of RecoveryIn-patient hospital stay, first post operative 48 hoursQuality of Recovery (QOR) score (0-18)
Duration of Hospital StayIn-patient hospital stay, average of 4-5 daysDuration of hospital stay (# of days)
Total In-hospital Cumulative Opioid ConsumptionIn-patient hospital stay average of 4 - 5 daysTotal in-hospital cumulative opioid consumption levels
Sedation LevelIn Hospital postoperative measures, average 4-5 daysSedation score in-patient
Pain Frequency and IntensityHospital discharge, average 4-5 days, 6 months and 1 year following dischargeShort-form McGill Pain Questionnaire Score
Anxiety and DepressionHospital discharge, average 4-5 days, 6 months and 1 year following dischargeHospital Anxiety and Depression Scale Score
Health Related Quality of LifeHospital discharge, average 4-5 days, 6 months and 1 year following dischargeShort-form health-related quality of life 36 Scores
Time to AmbulationIn-patient hospital stay, average 4-5 daysTime to ambulation (# of days)
Postoperative Nausea and VomitingIn Hospital postoperative measures, average 4-5 daysPostoperative nausea and vomiting (score of 0-3)

Countries

Canada

Participant flow

Participants by arm

ArmCount
Isotonic Saline (Control Group)
At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
44
Bupivacaine (Study Group)
At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
49
Total93

Baseline characteristics

CharacteristicIsotonic Saline (Control Group)Bupivacaine (Study Group)Total
Age, Continuous50.5 years
STANDARD_DEVIATION 8.4
52.1 years
STANDARD_DEVIATION 8.3
51.4 years
STANDARD_DEVIATION 8.3
Region of Enrollment
Canada
44 participants49 participants93 participants
Sex: Female, Male
Female
44 Participants49 Participants93 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
2 / 443 / 49
serious
Total, serious adverse events
0 / 440 / 49

Outcome results

Primary

Mean Total Opioid Consumption

The primary objective of this study is to compare the mean total opioid consumption in the first postoperative 48 hours between the control and study groups in intravenous morphine equivalent units. By directly blocking the neural afferents, the mean opioid consumption will be significantly lower in the group receiving intermittent local anaesthetic boluses compared to the placebo group through a TAP catheter.

Time frame: first postoperative 48 hours

ArmMeasureValue (MEAN)Dispersion
Isotonic Saline (Control Group)Mean Total Opioid Consumption30.0 mgStandard Deviation 19.1
Bupivacaine (Study Group)Mean Total Opioid Consumption20.7 mgStandard Deviation 20.1
p-value: 0.02Wilcoxon (Mann-Whitney)
Secondary

Anti-nausea Consumption

Total in-hospital cumulative anti-nausea consumption

Time frame: In-patient hospital stay, average 4-5 days

Secondary

Anxiety and Depression

Hospital Anxiety and Depression Scale Score

Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge

Secondary

Daily Pain Intensity Scores at Rest and With Movement

Daily pain intensity scores at rest and with movement using a visual pain analogue scale (0-10)

Time frame: In Hospital postoperative measures, average 4-5 days

Secondary

Duration of Hospital Stay

Duration of hospital stay (# of days)

Time frame: In-patient hospital stay, average of 4-5 days

Secondary

First Bowel Movement

Time to first bowel movement (# of days)

Time frame: In-patient hospital stay, average 4-5 days

Secondary

Health Related Quality of Life

Short-form health-related quality of life 36 Scores

Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge

Secondary

Pain Disability

Pain Disability Index Scores

Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge

Secondary

Pain Frequency and Intensity

Short-form McGill Pain Questionnaire Score

Time frame: Hospital discharge, average 4-5 days, 6 months and 1 year following discharge

Secondary

Postoperative Nausea and Vomiting

Postoperative nausea and vomiting (score of 0-3)

Time frame: In Hospital postoperative measures, average 4-5 days

Secondary

Quality of Recovery

Quality of Recovery (QOR) score (0-18)

Time frame: In-patient hospital stay, first post operative 48 hours

Secondary

Sedation Level

Sedation score in-patient

Time frame: In Hospital postoperative measures, average 4-5 days

Secondary

Time to Ambulation

Time to ambulation (# of days)

Time frame: In-patient hospital stay, average 4-5 days

Secondary

Total In-hospital Cumulative Opioid Consumption

Total in-hospital cumulative opioid consumption levels

Time frame: In-patient hospital stay average of 4 - 5 days

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026